ViGeneron and Biogen collaborate

ViGeneron signs global collaboration agreement for ophthalmic gene therapy development

05-Jan-2021 - ViGeneron GmbH announced a global collaboration and licensing agreement with Biogen Inc. to develop and commercialize gene therapy products based on adeno-associated virus (AAV) vectors to treat inherited eye diseases. The companies will use ViGeneron’s proprietary vgAAV, novel engineered AAV ...

Siemens and Biogen cooperate

Siemens Healthineers and Biogen announce agreement to jointly develop new MRI tools for multiple sclerosis

19-Jan-2017 - Siemens Healthineers and Biogen announced that the companies plan to jointly develop magnetic resonance imaging (MRI) applications with the intent of quantifying key markers of multiple sclerosis (MS) disease activity and progression. Siemens Healthineers aims to enable healthcare providers to ...

Antibody reduces harmful brain amyloid plaques in Alzheimer's patients

01-Sep-2016 - Aducanumab, an antibody developed by the University of Zurich, has been shown to trigger a meaningful reduction of harmful beta-amyloid plaques in patients with early-stage Alzheimer's disease. These protein deposits in the brain are a classic sign of Alzheimer's disease and contribute to the ...

Biogen names executive vice president

23-Jun-2016 - Biogen announced the appointment of Paul McKenzie, Ph.D., as executive vice president, Pharmaceutical Operations & Technology, effective July 1, 2016. He will report to George A. Scangos, Ph.D., chief executive officer, and will be a member of the Biogen management team. Dr. McKenzie was promoted ...

First etanercept biosimilar approved in the European Union

Biogen will manufacture and commercialize BENEPALI® in the EU

19-Jan-2016 - The joint venture between Biogen and Samsung BioLogics, Samsung Bioepis, has been granted European Commission (EC) approval for BENEPALI ® , an etanercept biosimilar referencing Enbrel ®. BENEPALI has been granted marketing authorization in the European Union (EU) for the treatment of adults with ...

Biogen Idec and Sobi announce positive top-line efficacy and safety results from phase 3 Alprolix paediatric study

04-Mar-2015 - Biogen Idec and Swedish Orphan Biovitrum AB announced positive top-line results of the Kids B-LONG Phase 3 clinical study that evaluated the safety, efficacy and pharmacokinetics of Alprolix® [Coagulation Factor IX (Recombinant), Fc Fusion Protein] in children under age 12 with severe haemophilia ...

Biogen Idec and Sobi announce positive top-line results from phase 3 study in hemophilia B

28-Sep-2012 - Biogen Idec and Swedish Orphan Biovitrum (Sobi)announced positive results from B-LONG, a clinical study that evaluated a new long-lasting clotting factor candidate in people with hemophilia B. Hemophilia B is a rare inherited disorder that impairs blood coagulation.Top-line results from B-LONG, a ...

Biogen Idec and Sobi Initiate Global Clinical Trials of Long-Lasting Hemophilia A and B Product Candidates in Children

09-Jul-2012 - Biogen Idec and Swedish Orphan Biovitrum announced the initiation of two global pediatric clinical trials of the companies' long-lasting recombinant Factor VIII and Factor IX Fc fusion proteins (rFVIIIFc and rFIXFc) in hemophilia A and B.rFVIIIFc and rFIXFc are fully-recombinant clotting factors ...

Biogen Idec and Abbott Announce Positive Top-Line Results from the First Registrational Trial for Daclizumab HYP in Relapsing-Remitting Multiple Sclerosis

SELECT Study Demonstrates Significant Reductions in Annualized Relapse Rate and Meets Key Secondary Endpoints

16-Aug-2011 - Biogen Idec and Abbott announced positive top-line results from SELECT, a global, registrational Phase 2b clinical trial designed to evaluate the investigational compound daclizumab high-yield process (DAC HYP) in people with relapsing-remitting multiple sclerosis (RRMS) over one year. Results ...

Biogen Idec and Swedish Orphan Biovitrum receive opinion from EMA on pediatric plan for long-lasting hemophilia B therapy

10-May-2011 - Biogen Idec and Swedish Orphan Biovitrum announced that the European Medicines Agency's (EMA) Pediatric Committee (PDCO) has adopted an opinion agreeing to the pediatric investigational plan for the companies' long-lasting, fully-recombinant Factor IX Fc fusion protein (rFIXFc).In accordance with ...